晚期上皮性卵巢癌的治疗标准主要是手术后接受铂类化疗，手术的目标是实现完全切除肿瘤。历史上，上皮性卵巢癌的细胞减灭手术是通过开放式腹腔探查手术进行的；然而，随着微创技术在妇科肿瘤学中越来越被广泛接受，将这种方法应用于上皮性卵巢癌的细胞减灭手术的兴趣也越来越大。本综述的目的是探讨目前关于微创手术与开放式腹腔探查手术作为上皮性卵巢癌间期细胞减灭手术方法之间的争议。虽然许多回顾性和可行性研究发现，微创和开放式腹腔探查手术在上皮性卵巢癌间期细胞减灭手术中实现完全切除的肿瘤残留程度、无进展生存和总体生存方面有相当的结果，但方法学挑战限制了这些数据的应用性。鉴于微创手术可能低估疾病负担和无法实现完全切除的潜在风险，需要进一步进行严格的研究，评估微创手术在此情况下的安全性和有效性，并更好地定义哪些患者能从微创手术中获得最大的好处。© 2023年。Asian Society of Gynecologic Oncology，Korean Society of Gynecologic Oncology，和Japan Society of Gynecologic Oncology。

The standard of care for treatment of advanced-stage epithelial ovarian cancer is primarily surgery followed by platinum-based chemotherapy, with the operative goal to achieve complete gross resection. Cytoreductive surgeries for epithelial ovarian cancer historically were performed via open laparotomy; however, as minimally invasive techniques became more widely accepted within gynecologic oncology, interest in employing this approach in the setting of cytoreductive surgery for epithelial ovarian cancer has grown. The purpose of this review was to examine the current debate between the use of minimally invasive surgery versus laparotomy as an approach to interval cytoreductive surgery in advanced epithelial ovarian cancer. While numerous retrospective and feasibility studies have found comparable outcomes with respect to complete gross residual disease, progression-free survival, and overall survival between minimally invasive and laparotomy approaches to interval cytoreductive surgery for epithelial ovarian cancer, methodological challenges limit the utility of these data. Given potential risks of underestimating disease burden and failing to achieve complete resection using a minimally invasive approach, further rigorous studies are needed to evaluate the safety and efficacy of minimally invasive surgery in this setting and to better define the subset of patients who would receive the greatest benefit from a minimally invasive approach.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.